Cardio Diagnostics Holdings (NASDAQ: CDIO), an artificial intelligence-driven precision cardiovascular medicine company, has published a whitepaper addressing diagnostic challenges in non-obstructive coronary artery disease (NOCAD), a condition where patients experience coronary disease symptoms without significant blockages in major arteries. The report, announced via Cardio Diagnostics Holdings (NASDAQ: CDIO), scrutinizes the limitations of invasive coronary angiography, which assesses coronary anatomy rather than function, and sheds light on ischemia with no obstructive coronary arteries (INOCA), a condition affecting an estimated 3 million to 4 million Americans.
The whitepaper examines NOCAD subgroups, diagnostic pathways, and opportunities to improve detection of coronary disease that may evade conventional angiography. It also outlines clinical approaches to identifying patients earlier, including the potential role of epigenetics-based testing in primary care. Cardio Diagnostics highlighted its ongoing efforts to build clinical evidence supporting PrecisionCHD, its AI- and epigenetics-based blood test designed to aid in diagnosing coronary heart disease, including its potential application in identifying patients with INOCA whose symptoms remain unexplained by traditional testing.
This announcement matters because NOCAD and INOCA often go undiagnosed, leaving millions of patients without clear explanations or appropriate care. Invasive coronary angiography, the current standard for evaluating coronary artery disease, focuses on structural blockages and may miss functional impairments in smaller vessels or the microcirculation. By drawing attention to these gaps, Cardio Diagnostics aims to shift attention toward functional and epigenetic markers that could enable earlier, non-invasive detection in primary care settings. The whitepaper’s emphasis on epigenetics-based testing aligns with broader trends in precision medicine, where molecular signatures are used to tailor diagnostics and treatment. If validated, such tests could reduce reliance on invasive procedures, lower healthcare costs, and improve outcomes for patients whose symptoms are dismissed due to normal angiograms.
For investors and industry observers, the release signals Cardio Diagnostics’ continued investment in clinical evidence for PrecisionCHD. The company’s proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine (Core Technology) underpins its efforts to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The full press release is available at https://ibn.fm/N5RnS, and ongoing news and updates about CDIO can be found in the company’s newsroom at https://ibn.fm/CDIO. The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
